NO20056188L - Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes - Google Patents

Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes

Info

Publication number
NO20056188L
NO20056188L NO20056188A NO20056188A NO20056188L NO 20056188 L NO20056188 L NO 20056188L NO 20056188 A NO20056188 A NO 20056188A NO 20056188 A NO20056188 A NO 20056188A NO 20056188 L NO20056188 L NO 20056188L
Authority
NO
Norway
Prior art keywords
diabetes
abl
pdgf
treatment
tyrosine kinase
Prior art date
Application number
NO20056188A
Other languages
English (en)
Other versions
NO331715B1 (no
Inventor
Robert Per Hagerkvist
Nils Richard Welsh
Original Assignee
Nils Richard Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Nils Richard Welsh filed Critical Nils Richard Welsh
Publication of NO20056188L publication Critical patent/NO20056188L/no
Publication of NO331715B1 publication Critical patent/NO331715B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives anvendelse av c-Abl-, PDGF-R- eller c-kit tyrosinkinaseinhibitorer, for eksempel 4-(4- metylpiperazin-l-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2ylamino)fenyl]-benzamid eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for behandling av diabetes, for eksempel type I diabetes eller type II diabetes.
NO20056188A 2003-05-27 2005-12-23 Anvendelse av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller prevensjon av diabetes NO331715B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2004/005679 WO2004105763A2 (en) 2003-05-27 2004-05-26 Use of tyrosine kinase inhibitor to treat diabetes

Publications (2)

Publication Number Publication Date
NO20056188L true NO20056188L (no) 2005-12-23
NO331715B1 NO331715B1 (no) 2012-03-05

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20056188A NO331715B1 (no) 2003-05-27 2005-12-23 Anvendelse av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller prevensjon av diabetes

Country Status (21)

Country Link
US (1) US7875616B2 (no)
EP (1) EP1631291B1 (no)
JP (1) JP4776537B2 (no)
KR (1) KR101102229B1 (no)
AT (1) ATE439133T1 (no)
BR (1) BRPI0410704A (no)
CA (1) CA2526594C (no)
DE (1) DE602004022540D1 (no)
DK (1) DK1631291T3 (no)
ES (1) ES2331800T3 (no)
HK (1) HK1087638A1 (no)
IL (1) IL171927A (no)
IS (1) IS2712B (no)
MA (1) MA27812A1 (no)
MX (1) MXPA05012739A (no)
NO (1) NO331715B1 (no)
NZ (1) NZ543709A (no)
PL (1) PL1631291T3 (no)
PT (1) PT1631291E (no)
RU (1) RU2365373C2 (no)
WO (1) WO2004105763A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535242A1 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
JPWO2008001885A1 (ja) * 2006-06-30 2009-11-26 協和発酵キリン株式会社 Ａｂｌキナーゼ阻害剤
JP2014526506A (ja) * 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (no) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
PT1033364E (pt) * 1999-03-01 2005-07-29 Pfizer Prod Inc Ciano com acidos oxamicos e derivados como ligandos de receptores de tiroide
SK12992002A3 (sk) * 2000-02-15 2003-05-02 Teva Pharmaceutical Industries Ltd. Spôsob syntézy leflunomidu
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2004518669A (ja) * 2000-12-20 2004-06-24 スージェン・インコーポレーテッド ４−アリール置換インドリノン
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
WO2004043408A2 (en) * 2002-11-13 2004-05-27 Genpath Pharmaceuticals, Incorporated Gpc15: methods and compositions for treating cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
NO331715B1 (no) 2012-03-05
CA2526594C (en) 2011-11-08
ES2331800T3 (es) 2010-01-15
MA27812A1 (fr) 2006-03-01
IL171927A (en) 2011-10-31
US7875616B2 (en) 2011-01-25
HK1087638A1 (en) 2006-10-20
US20070072932A1 (en) 2007-03-29
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
KR101102229B1 (ko) 2012-01-05
KR20060021865A (ko) 2006-03-08
DE602004022540D1 (de) 2009-09-24
NZ543709A (en) 2009-04-30
PL1631291T3 (pl) 2010-04-30
WO2004105763A2 (en) 2004-12-09
AU2004243491A1 (en) 2004-12-09
RU2005140516A (ru) 2007-07-10
JP2006528225A (ja) 2006-12-14
EP1631291B1 (en) 2009-08-12
BRPI0410704A (pt) 2006-06-13
ATE439133T1 (de) 2009-08-15
MXPA05012739A (es) 2006-05-17
JP4776537B2 (ja) 2011-09-21
IL171927A0 (en) 2006-04-10
DK1631291T3 (da) 2009-11-02
CA2526594A1 (en) 2004-12-09
EP1631291A2 (en) 2006-03-08
WO2004105763A3 (en) 2005-06-02
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22

Similar Documents

Publication Publication Date Title
DK1332137T3 (da) Behandling af gastrointestinale stromale tumorer
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
NO20052755D0 (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmate for dens fremstilling og dens anvendelse.
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
PE20071086A1 (es) DERIVADOS DE PIRAZOLOISOQUINOLINA COMO INHIBIDORES DE LA CINASA p38
ATE399555T1 (de) Behandlung der rheumatoiden arthritis mit imitanib
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
ATE492277T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-( -(pyridin-3-yl)pyrimidin-2- ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
TN2011000037A1 (en) Treatment of pulmonary arterial hypertension

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees